alexa Study of Methyl Dopa Versus Labetalol in Management of
ISSN: 2161-0932

Gynecology & Obstetrics
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Research Article

Study of Methyl Dopa Versus Labetalol in Management of Preeclampsia and Gestational Hypertension

Dharwadkar MN1, Kanakamma MK1, Dharwadkar SN2*, Rajagopal K1, Gopakumar C3, Divya James Fenn J4 and Balachandar V3,5

1Department of Obstetrics and Gynaecology, Yenepoya Medical College and teaching Hospital, Yenepoya University, Deralakatte, Mangalore, Karnataka 575022, India

2Department of Zoology, K.L.E’s. S. Nijalingappa College, KLE Medical University (Health), Bangalore, Karnataka 560010, India

3Department of Human Genetics Molecular Biology, Bharathiar University, Coimbatore, India

4Post Graduate Student, Department of Obstetrics and Gynaecology, Sree Balaji Medical College and Hospital, Chennai 600044, Tamil Nadu, India

5Human Molecular Genetics Laboratory, Department of Zoology, Bharathiar University, Coimbatore, India

*Corresponding Author:
Dharwadkar SN
Department of Zoology
K.L.E′s. S. Nijalingappa College
KLE Medical University (Health)
Bangalore, Karnataka 560010, India
Tel: +91 998612290
E-mail: [email protected]

Received date: May 27, 2014; Accepted date: September 12, 2014; Published date: September 15, 2014

Citation: Dharwadkar MN, Kanakamma MK, Dharwadkar SN, Rajagopal K, Gopakumar C, et al. (2014) Study of Methyl Dopa Versus Labetalol in Management of Preeclampsia and Gestational Hypertension. Gynecol Obstet (Sunnyvale) 4:242 doi:10.4172/2161-0932.1000242

Copyright: © 2014 Dharwadkar MN, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

 

Abstract

Objective: To assess the efficacy and safety of labetalol compared with methyldopa in the management of mild and moderate cases of pregnancy-induced hypertension (PIH). Methods: Eighty patients with PIH were randomly allocated to receive either labetalol (group A) or methyldopa (group B). Administration of drugs with respect to Age, Gravid Status, Blood Pressure, Urine albumin Levels, Side Effects, Drug dosage, Additional Treatment, Prolongation of Pregnancy, New born Screening Test (NST), mode of termination, Indication of caesarean section, Perinatal safety and APGAR scores were studied. The statistical level of significance was taken at P<0.05. Results: A labetalol has been very effective in control as well as earlier onset of action in patients with methyl dopa. With effective control of blood pressure, prevention of eclampsia and the pregnancy can be prolonged to achieve fetal maturity. Labetalol has lesser side effects when compared to methyldopa. Labetalol is not associated with adverse fetal effects in the immediate and late neonatal period. The chances of spontaneous onset of labor were greater in the labetalol group when compared to methyldopa group. Though there was no difference in the groups with regard to obstetric intervention. At clinically effective doses, both the drugs were found to be safe for the neonate. Conclusions: Labetalol is safer, quicker in achieving adequate control of blood pressure with considerable prolongation of the duration of pregnancy with fewer side effects on the mother as well as the neonate when used in the management hypertensive disorders of pregnancy.

Keywords

Share This Page

Additional Info

Loading
Loading Please wait..
 
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords